Kathy S. Frommer Elected to the Board of Directors
CHESTER, N.Y.–(BUSINESS WIRE)– Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical”) today announced that shareholders voted in favor of all items of business put forth at the company’s Annual Meeting of Shareholders held on April 23, 2019 in Chester, NY.
Shareholders elected director nominee Kathy S. Frommer as a new, independent member of the Board of Directors succeeding Mark L. Pastreich. Shareholders also re-elected Daniel S. Goldberger, Robert T. Allen, David W. Anderson, James M. Beck, Joseph M. Manko, Jr., and Arthur J. Radin to the Board of Directors. As previously announced, Mr. Radin died unexpectedly on April 24, 2019.
“On behalf of the Board of Directors, I want to welcome Kathy Frommer to her new role and thank Mark Pastreich for his many years of loyal service to RMS Medical,” said Daniel S. Goldberger, Executive Chairman. “We believe we are well-positioned to expand our business and elevate our profile in the growing home and alternate site infusion industry.”
Mrs. Frommer brings more than 30 years of experience in the information technology industry to RMS Medical. In 1989, she co-founded CRS Retail Systems (“CRS”), one of the largest providers of software for specialty store retailers in the United States and served as Chief Executive Officer until its acquisition by Epicor Software in 2005. During her tenure at CRS, Mrs. Frommer successfully guided the company through extensive growth, multiple acquisitions, and major technology initiatives, as well as a successful partnership with private equity firm Accel-KKR. With systems installed worldwide, the solutions offered by CRS helped its customers drive sales, improve customer service and reduce operating costs. Prior to CRS, Mrs. Frommer worked as a systems engineer with various technology companies. She currently serves on the Board of the SUNY Orange College Foundation and the Bethel Woods Center for the Arts.
Shareholders also approved, on an advisory basis, the compensation of RMS Medical’s executive officers and the frequency of future votes on executive compensation; the ratification of the appointment of RMS Medical’s independent registered public accountants for the 2019 fiscal year; and an increase in the maximum number of shares that may be awarded under the 2015 Stock Option Plan.
About RMS Medical Products
RMS Medical develops, manufactures and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information about RMS Medical, please visit www.rmsmedicalproducts.com.
The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties, identified by words such as “believe”. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. RMS Medical undertakes no obligation to update any forward-looking statements.